Loxo Oncology, Inc. (LOXO) has 161 open-market insider trades by 31 insiders since 2001. The most active filer is Joshua H. Bilenker, CEO & President.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Andrew N. Schiff | 10% Owner | — | 1 | $251.2M | 2018-07-10 |
| David P. Bonita | Dir | — | 5 | $105.3M | 2017-12-08 |
| Joshua H. Bilenker | CEOPres | — | 46 | $78.7M | 2019-02-15 |
| Steve Elms | Dir10% Owner | — | 2 | $42.9M | 2019-02-15 |
| Samuel D. Isaly | Dir | — | 1 | $36.9M | 2017-11-16 |
| Aisling Capital Partners III LLC | Dir10% Owner | — | 4 | $34.3M | 2017-12-19 |
| Keith T. Flaherty | Dir | — | 9 | $20.2M | 2019-02-15 |
| Jacob van Naarden | — | — | 35 | $17.9M | 2019-02-15 |
| Lori Anne Kunkel | Dir | — | 7 | $16.8M | 2018-10-01 |
| Deerfield Mgmt L.P. via James E. Flynn | 10% | — | 1 | $14.2M | 2014-08-06 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Avi Z. Naider | Director | Buy | $201K | 2018-12-13 |
| Jacob van Naarden | — | Sell | $426K | 2018-12-11 |
| Joshua H. Bilenker | CEO & President | Sell | $1.0M | 2018-12-11 |
| Jennifer Burstein | VP | Sell | $80K | 2018-12-11 |
| Jacob van Naarden | — | Sell | $1.2M | 2018-12-10 |
| Joshua H. Bilenker | CEO & President | Sell | $1.0M | 2018-12-10 |
Companies that share insiders with LOXO, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Jacob van Naarden | — | Sell | $120K | 2018-12-10 |
| Jennifer Burstein | VP | Sell | $339K | 2018-12-10 |
| Joshua H. Bilenker | CEO & President | Sell | $2.7M | 2018-12-10 |
| Jennifer Burstein | VP | Sell | $74K | 2018-12-10 |
| Jacob van Naarden | — | Sell | $293K | 2018-11-27 |
| Joshua H. Bilenker | CEO & President | Sell | $1.2M | 2018-11-27 |
| Joshua H. Bilenker | CEO & President | Sell | $2.9M | 2018-11-26 |
| Jacob van Naarden | — | Sell | $487K | 2018-11-26 |
| Jacob van Naarden | — | Sell | $1.5M | 2018-11-26 |